Hutchmed (China) Newsroom

UBS Group: Maintains Buy rating on Hutchmed (China) (00013) with the Target Price lowered to HKD 38.7.

Zhitong FinanceJan 8 14:35

Major bank rating丨BOCOM INTL: Raised the Target Price of Hutchmed (China) to HKD 44, maintaining a "Buy" rating.

Gelonghui FinanceJan 8 10:48

BOCOM INTL: Maintains Buy rating for Hutchmed (China) (00013) with the Target Price raised to 44 HKD.

Zhitong FinanceJan 8 09:27

[Brokerage Focus] BOCOM INTL raised the Target Price for Hutchmed (China) (00013) by 8.9%, stating that the sale of affiliated company equity is beneficial for the company's long-term development.

Jinwu Financial NewsJan 8 09:15

BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $26

Futu NewsJan 7 20:31

Hewang Pharmaceutical (0013.HK): Selling non-core assets with sufficient cash flow to promote ATTC R&D

Pu Silver InternationalJan 7 00:00

Hehuang Pharmaceutical (0013.HK): Excellent consideration for the sale of joint company equity pipeline, impressive increase in target price

BOCOM INTLJan 7 00:00

Hewang Pharmaceutical (0013.HK): Sale of non-core Chinese medicine assets focuses on innovation and implementation

GTJAJan 5 00:00

[Brokerage Focus] Southwest Securities maintains a "Buy" rating for Hutchmed (China) (00013), indicating promising commercial prospects for fruquintinib in the future.

Jinwu Financial NewsJan 3 17:30

Huhuang Pharmaceutical (0013.HK): Successful NDA for sale of non-core joint venture sevotinib

Southwest SecuritiesJan 3 15:02

GF SEC: Maintain the "Buy" rating for Hutchmed (China) (00013) with a fair value of 41.35 HKD.

Zhitong FinanceJan 3 09:37

Hehuang Pharmaceutical (00013.HK): Savotinib successfully sold traditional Chinese medicine assets accepted by domestic NDA for second-line lung cancer

GF SECJan 2 00:00

Hehuang Pharmaceutical (0013.HK): Sailing in the Blue Ocean and Starting a New Journey to Overseas Markets

HTSCDec 30, 2024 19:22

Orient: Initiates a "Buy" rating for Hutchmed (China) (00013) with a Target Price of 33.24 HKD.

Zhitong FinanceDec 27, 2024 09:19

【Brokerage Focus】Orient gives Hutchmed (China) (00013) an initial "Buy" rating as innovative products yield results.

Jinwu Financial NewsDec 27, 2024 09:10

Hehuang Pharmaceutical (00013.HK): PIPELINE has blossomed and the results of going out to sea are being realized

OrientDec 27, 2024 07:32

Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target

MT NewswiresDec 19, 2024 20:40

GF Securities: Maintaining the reasonable value of Hewang Pharmaceutical's (00013) “buy” rating of HK$41.35

Zhitong FinanceDec 12, 2024 09:32

Hehuang Pharmaceutical (00013.HK): New Indications for Fruquintinib Approved to Verify Combined Therapy Potential

GF SECDec 10, 2024 00:00

Hehuang Pharmaceutical (00013.HK): Progress has been made in clinical development and commercialization

guosenDec 3, 2024 07:42